CSF3 and myocardial infarction: Four weeks later, we used CAG, LVG, TTE, CMR, and SPECT to compare their outcomes, observing that the pigs in middle-dose (5 μg/kg/d) group had better cardiac function, smaller myocardial infarct size, richer blood perfusion, more surviving myocardium, and milder ventricular remodeling not only than the controls, but also than those treated with other dosages of G-CSF, either higher or lower (2.5 or 10 μg/kg/d).